Data News > Stock News Roundup: Recent Inducement Grants and Delisting Announcements
- Mirum Pharmaceuticals and Crinetics Pharmaceuticals report inducement grants under Nasdaq Listing Rule 5635(c)(4)
- Delisting of securities of various companies from The Nasdaq Stock Market
- Xilio Therapeutics, Axogen, and Jaguar Health announce new employee inducement grants
- Nasdaq releases end-of-month open short interest positions in Nasdaq stocks
- 3 E Network Technology Group Limited closes Nasdaq initial public offering
Mirum Pharmaceuticals and Crinetics Pharmaceuticals recently reported inducement grants under Nasdaq Listing Rule 5635(c)(4). While Mirum Pharmaceuticals based in Foster City, California, did not divulge the exact details of the grants, Crinetics Pharmaceuticals, headquartered in San Diego, provided more specifics. On January 10, 2025, the Compensation Committee of Crinetics Pharmaceuticals' Board of Directors granted non-qualified stock option awards to sixteen new non-executive employees and 100,000 shares to one new executive employee under the company's 2021 Inducement Plan.
In other news, several companies are facing delisting from The Nasdaq Stock Market. BIMI International Medical Inc., The Dixie Group, Inc., and several others are among those affected by this decision, with their common stock facing delisting due to various reasons such as suspension and lack of trading activity.
Xilio Therapeutics, Axogen, and Jaguar Health have each announced new employee inducement grants. Xilio Therapeutics, a clinical-stage biotechnology company based in Waltham, Massachusetts, granted a non-qualified stock option to purchase 375,000 shares of its common stock to Caroline Hensley, the newly hired Chief Legal Officer. Meanwhile, Axogen introduced Craig Swandal as the new VP of Operations and provided an inducement grant under Nasdaq Listing Rule 5635(c)(4). Jaguar Health, headquartered in San Francisco, granted restricted stock units (RSUs) to three new employees, with different vesting periods for each.
Nasdaq has released the end-of-month open short interest positions in Nasdaq stocks as of the settlement date of December 31, 2024. The total short interest in 3,085 Nasdaq Global Market securities amounted to 12,137,206,474 shares, showing a slight decrease from the previous reporting period.
Lastly, 3 E Network Technology Group Limited, a company based in Guangzhou, China, announced the closing of its Nasdaq initial public offering. The Offering consisted of 1,250,000 Class A ordinary shares priced at US$4.00 per share. The Class A ordinary shares began trading on the Nasdaq Capital Market under the ticker symbol "MASK" on January 8, 2025.
Overall, the recent stock market developments include inducement grants, delisting announcements, short interest positions, and an initial public offering closure, reflecting the dynamic nature of the financial market.
For more information:
Up/Down Rally Price Distribution Analyst Recommendations Earning Price Impact Analysis Seasonality
Stock News Roundup: Recent Inducement Grants and Delisting Announcements
By KlickAnalytics Data Insights | January 10, 2025 08:03PM ET
Key Points
- Mirum Pharmaceuticals and Crinetics Pharmaceuticals report inducement grants under Nasdaq Listing Rule 5635(c)(4)
- Delisting of securities of various companies from The Nasdaq Stock Market
- Xilio Therapeutics, Axogen, and Jaguar Health announce new employee inducement grants
- Nasdaq releases end-of-month open short interest positions in Nasdaq stocks
- 3 E Network Technology Group Limited closes Nasdaq initial public offering
Mirum Pharmaceuticals and Crinetics Pharmaceuticals recently reported inducement grants under Nasdaq Listing Rule 5635(c)(4). While Mirum Pharmaceuticals based in Foster City, California, did not divulge the exact details of the grants, Crinetics Pharmaceuticals, headquartered in San Diego, provided more specifics. On January 10, 2025, the Compensation Committee of Crinetics Pharmaceuticals' Board of Directors granted non-qualified stock option awards to sixteen new non-executive employees and 100,000 shares to one new executive employee under the company's 2021 Inducement Plan.
In other news, several companies are facing delisting from The Nasdaq Stock Market. BIMI International Medical Inc., The Dixie Group, Inc., and several others are among those affected by this decision, with their common stock facing delisting due to various reasons such as suspension and lack of trading activity.
Xilio Therapeutics, Axogen, and Jaguar Health have each announced new employee inducement grants. Xilio Therapeutics, a clinical-stage biotechnology company based in Waltham, Massachusetts, granted a non-qualified stock option to purchase 375,000 shares of its common stock to Caroline Hensley, the newly hired Chief Legal Officer. Meanwhile, Axogen introduced Craig Swandal as the new VP of Operations and provided an inducement grant under Nasdaq Listing Rule 5635(c)(4). Jaguar Health, headquartered in San Francisco, granted restricted stock units (RSUs) to three new employees, with different vesting periods for each.
Nasdaq has released the end-of-month open short interest positions in Nasdaq stocks as of the settlement date of December 31, 2024. The total short interest in 3,085 Nasdaq Global Market securities amounted to 12,137,206,474 shares, showing a slight decrease from the previous reporting period.
Lastly, 3 E Network Technology Group Limited, a company based in Guangzhou, China, announced the closing of its Nasdaq initial public offering. The Offering consisted of 1,250,000 Class A ordinary shares priced at US$4.00 per share. The Class A ordinary shares began trading on the Nasdaq Capital Market under the ticker symbol "MASK" on January 8, 2025.
Overall, the recent stock market developments include inducement grants, delisting announcements, short interest positions, and an initial public offering closure, reflecting the dynamic nature of the financial market.
For more information:
Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.